Farnesyl Transferase Inhibitor

Farnesyl Transferase Inhibitors (48):

Cat. No.	Product Name	Effect	Purity

HY-10502

Tipifarnib	Inhibitor	99.89%
Tipifarnib (IND 58359) binds to and inhibits farnesyltransferase (FTase) with an IC₅₀ of 0.86 nM. Antineoplastic activity and antiparasitic activity.

HY-15136

Lonafarnib	Inhibitor	99.87%
Lonafarnib (Sch66336) is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of H-ras, K-ras and N-ras with IC₅₀ values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.

HY-16273A

L-778123 hydrochloride	Inhibitor	98.96%
L-778123 hydrochloride is a dual inhibitor of FPTase and GGPTase-I, with IC₅₀ values of 2 nM and 98 nM respectively.

HY-N6796

Manumycin A	Inhibitor	99.27%
Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion.

HY-100313A

YM-53601	Inhibitor	99.26%
YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo. YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent. YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation.

HY-116254

L-739750	Inhibitor
L-739750 is a selective protein farnesyltransferase (PFTase) inhibitor (IC₅₀: 0.4 nM). PFTase utilizes farnesyl diphosphate to farnesylate the cysteine residue of protein substrates having a C-terminal CAAX motif. L-739750 is a selective CAAX peptidomimetic.

HY-120763

LB42908	Inhibitor
LB42908 is a potent, selective and orally active farnesyltransferase inhibitor. LB42908 inhibits farnesylation of H-Ras, K-Ras with IC₅₀ values of 0.9 nM, 2.4 nM for H-Ras, K-Ras, respectively. LB42908 shows antiproliferative activity. LB42908 shows antitumor activity.

HY-125311

Zaragozic acid D	Inhibitor
Zaragozic acid D is a squalene synthase inhibitor. Zaragozic acid D also is a farnesyl-protein transferase (FPTase) inhibitor with an IC₅₀ value of 100 nM for bovine FPTase.

HY-15872A

FTI-277 hydrochloride	Inhibitor	98.29%
FTI-277 hydrochloride is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling. FTI-277 hydrochloride can inhibit hepatitis delta virus (HDV) infection.

HY-16373

CP-609754	Inhibitor	99.21%
CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC₅₀ for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL. CP-609754 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-16059

Arglabin	Inhibitor	99.87%
Arglabin ((+)-Arglabin), a natural product isolated from Artemisia glabella, is a NLRP3 inflammasome inhibitor. Arglabin shows anti-inflammatory and antitumor activities. The antitumor activity of Arglabin proceeds through its inhibition of farnesyl transferase which leads to the activation of RAS proto-oncogene.

HY-128350

FGTI-2734	Inhibitor	99.64%
FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC₅₀s of 250 nM and 520 nM for FT and GGT-1, respectively. FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors.

HY-16111

BMS-214662	Inhibitor	99.58%
BMS-214662 is a potent and selective farnesyl transferase inhibitor with potent antitumor activity with an IC₅₀ of 1.35 nM.

HY-15873A

FTI 276 TFA	Inhibitor	98.06%
FTI-276 is a protein farnesyl transferase (PFT) inhibitor with IC₅₀s of 0.9 nM and 0.5 nM for Plasmodium falciparum and human, respectively.

HY-128350A

FGTI-2734 mesylate	Inhibitor	99.65%
FGTI-2734 mesylate is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor with IC₅₀s of 250 nM and 520 nM for FT and GGT, respectively. FGTI-2734 mesylate can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors.

HY-123242

FTI-2153	Inhibitor	99.11%
FTI-2153 is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC₅₀ of 1.4 nM. FTI-2153 is >3000-fold more potent at blocking H-Ras (IC₅₀, 10 nM) than Rap1A processing. Anti-cancer activity.

HY-15879

LB42708	Inhibitor	≥99.0%
LB42708 is a potent, selective and orally active farnesyltransferase inhibitor. LB42708 inhibits farnesylation of H-Ras, N-Ras and K-Ras4B with IC₅₀s of 0.8 nM, 1.2 nM and 2.0 nM, respectively.

HY-119257

ABT-100	Inhibitor	98.18%
ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC₅₀s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity.

HY-123242A

FTI-2153 TFA	Inhibitor	99.11%
FTI-2153 TFA is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC₅₀ of 1.4 nM. FTI-2153 TFA is >3000-fold more potent at blocking H-Ras (IC₅₀, 10 nM) than Rap1A processing. Anti-cancer activity.

HY-15873

FTI 276	Inhibitor
FTI-276 is a protein farnesyl transferase (PFT) inhibitor with IC₅₀s of 0.9 and 0.5 nM for Plasmodium falciparum and human.

Name
Email *

	Sorry, but the email address you supplied was invalid.